

FOR IMMEDIATE RELEASE

CORE LAB ANNOUNCES THE RESULTS OF ITS 2017 ANNUAL SHAREHOLDER MEETING

AMSTERDAM (22 May 2017) – Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") announces it held its annual shareholder meeting on May 18, 2017 in Amsterdam, The Netherlands. At that meeting, the shareholders re-elected Mr. Demshur and Mr. Sodderland to the supervisory board. The vote results for all matters voted upon at the annual meeting of shareholders on May 18, 2017 are as follows:

<u>Proposal No. 1 - Election of Class I Directors</u>: The election of each Class I supervisory director was approved as follows:

Nominee	For	Withheld	Broker Non-Votes
David M. Demshur	33,588,078	2,448,225	0
Jan Willem Sodderland	35,640,406	395,897	0

<u>Proposal No. 2 – Amendment of Articles of Association</u>: To amend Article 20, paragraph 5(ii), of our Articles of Association to allow for any future amendments to the Articles of Association which are proposed by the board of management and which proposal is approved by the board of supervisory directors, to be passed with an absolute majority of votes cast, with regard to the number of shares represented at the meeting was approved as follows:

For	Against	Abstentions	Broker Non-Votes
26,509,933	9,437,706	88,664	0

<u>Proposal No. 3 – Appointment of KPMG</u>: The appointment of KPMG as the Company's independent registered public accountants for the fiscal year ending December 31, 2017 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
·			
35,828,511	48,406	159,386	0

<u>Proposal No. 4 - Approve the Compensation of the Company's Executive Officers</u>: The compensation program regarding the Company's named executive officers was approved as follows:

For	Against	Abstentions	Broker Non-Votes
		· ·	
33,614,931	2,240,585	180,787	0

<u>Proposal No. 5 - Confirm and Adopt the Dutch Statutory Annual Accounts:</u> The confirmation and adoption of the Company's Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2016 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
35,818,996	17,714	199,593	0

<u>Proposal No. 6 - Approve and Resolve the Cancellation of Repurchased Shares</u>: The approval of the cancellation of the Company's repurchased shares held by the Company in its name at 12:01 a.m. CEST on May 18, 2017 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
35,829,823	27,788	178,692	0

<u>Proposal No. 7 - Approve Extension - Repurchase up to 10% of Issued Share Capital</u>: The approval of the extension of the existing authority to repurchase up to 10% of the Company's issued share capital until November 18, 2018 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
35,801,126	56,034	179,143	0

<u>Proposal No. 8 - Approve Extension to Issue Shares and/or Grant Rights</u>: The approval of the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to the Company's common and preference shares up to a maximum of 10% of outstanding shares per annum until November 18, 2018 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
35,693,135	165,443	177,725	0

<u>Proposal No. 9 - Approve Extension to Limit or Exclude Preemptive Rights</u>: The approval of the extension of the authority to limit or exclude the preemptive rights of the holders of the Company's common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 16, 2014 was approved as follows:

For	Against	Abstentions	Broker Non-Votes
34,783,344	1,057,126	195,833	0

Core Laboratories N.V. (www.corelab.com) is a leading provider of proprietary and patented reservoir description, production enhancement, and reservoir management services used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing region in the world.

For more information contact:

Richard L. Bergmark - CFO, +1 713 328 2101

Gwen Y. Schreffler - VP Corporate Development and Investor Relations, +1 713 328 6210 investor.relations@corelab.com

####